title: [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
abstract: The results of the treatment with lymphoblastoid alpha interferon (IFN-alpha N1) in 10 patients with chronic myeloid leukaemia who had poor response to previous recombinant alpha interferon (rIFN-alpha) are presented. Eight of these patients had not developed anti-alpha 2 interferon antibodies, and 2 had non-neutralising anti-IFN antibodies. Three of the 10 patients received benefit from IFN-alpha N1 treatment. Two of them, with no response to rIFN alpha 2, attained complete haematologic response wit IFN-alpha N1. Cytogenetic responses although minimal, were achieved as well. The third patient, after receiving rIFN-alpha for 3 years with no response, had partial cytogenetic response after 4 months of treatment with IFN-alpha N1. These results suggest that IFN-alpha N1 when used in patients refractory to IFN-alpha N1. These results suggest that IFN-alpha N1 when used in patients refractory to IFN alpha 2 without anti-IFn alpha 2 neutralising antibodies may be useful in a minority of patients, although the frequency of cytogenetic responses is low.
authors.affiliation: Servicio de Hematología, Hospital de la Princesa, Madrid.
authors.forename: J L
authors.initials: JL
authors.lastname: Steegmann
authors.forename: E
authors.initials: E
authors.lastname: Granados
authors.forename: L
authors.initials: L
authors.lastname: Vázquez
authors.forename: R
authors.initials: R
authors.lastname: de la Cámara
authors.forename: M J
authors.initials: MJ
authors.lastname: Peñarrubia
authors.forename: E
authors.initials: E
authors.lastname: Fernández-Contreras
authors.forename: J A
authors.initials: JA
authors.lastname: Quiroga
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández Rañada
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins
vernacular_title: Tratamiento con interferón alfa linfoblastoide en pacientes con leucemia mieloide crónica resistente a interferón alfa 2 recombinante.